Aurora Cannabis Inc. (ACB)
Pre-market:
| Previous close | 5.68 |
| Open | 5.61 |
| Bid | 5.87 x 100 |
| Ask | 5.91 x 300 |
| Day's range | 5.54 - 5.91 |
| 52-week range | 2.84 - 11.50 |
| Volume | |
| Avg. volume | 7,935,019 |
| Market cap | 321.838M |
| Beta (5Y monthly) | 2.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -57.47 |
| Earnings date | 12 Jun 2024 - 17 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.79 |
PR NewswireAurora Cannabis to Host Fourth Quarter and Fiscal Year 2024 Investor Conference Call and File Related Year End Information
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2024 before the opening of markets that same day.
PR NewswireAurora Unveils Premium Resin Cartridges in Australia
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is excited to announce the launch of its premium 1.2g resin cartridges in Australia. This expansion marks a significant step in Aurora's mission to provide high-quality products to patients worldwide. Now available for doctors to prescribe to patients in Australia, Aurora's new resign cartridges, developed and manufactured at the company's EU-GMP an
ZacksSol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
